TokenPost·
Genmab and Incyte Plan Phase 1/2 Trial for KRAS-Mutated Metastatic Colorectal Cancer
The study will combine petosemtamab and INCB161734 with chemotherapy as a potential first-line treatment.
More news
- Bitcoin.com NewsBitcoin’s 7-Day Hashrate Returns to 1 ZH/s After Nearly 8 Months
- TokenPostPiedmont Realty Trust Schedules Q3 Results Release for Oct. 26
- TokenPostBTW Listings Differ on Labels for 101.6 Million Tokens Listed for Nov. 2
- TokenPostTPG RE Finance Trust to Release Q3 Results After Monday's Market Close
- Crypto BriefingSpaceX closes $40 billion in debt financing to buy GPUs
- TokenPostGrok Releases Seven-Minute First Episode of AI-Generated ‘Odyssey’